Amryt Pharmaceuticals Inc. Sustainability Profile
Amryt Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across Europe and other key regions. Founded in 2015, the company has rapidly established itself as a leader in developing innovative treatments for rare and orphan diseases, particularly in dermatology and metabolic disorders. Amryt's core products, including the unique topical treatment AP101 for epidermolysis bullosa, highlight its commitment to addressing unmet medical needs. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, which have bolstered its market position. With a focus on patient-centric solutions, Amryt Pharmaceuticals continues to make strides in improving the lives of those affected by rare diseases, solidifying its reputation as a trusted name in the biopharmaceutical landscape.
DitchCarbon Score
How does Amryt Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharmaceuticals Inc.'s score of 47 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amryt Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Amryt Pharma plc, which may influence its climate commitments and emissions reporting. As part of its corporate family, Amryt Pharmaceuticals Inc. inherits climate initiatives and targets from its parent company, Chiesi Farmaceutici S.p.A., at a cascade level of three. However, there are no documented reduction targets or specific climate pledges available for Amryt Pharmaceuticals Inc. at this time. The absence of emissions data and reduction initiatives suggests that Amryt Pharmaceuticals Inc. may still be in the early stages of developing its climate strategy. The company’s commitment to sustainability and carbon reduction will likely align with the broader goals set by its parent organisation, Chiesi Farmaceutici S.p.A., which is known for its efforts in environmental responsibility. In summary, while Amryt Pharmaceuticals Inc. does not currently report specific emissions figures or reduction targets, its climate commitments may be influenced by the initiatives of its parent company, Chiesi Farmaceutici S.p.A. Further developments in their sustainability strategy are anticipated as the company progresses in its environmental efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 33,911,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,835,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 742,267,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Amryt Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Amryt Pharmaceuticals Inc.'s Location?
Amryt Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amryt Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
